Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ANVS Annovis Bio	$2.38 +0.1%	$2.62	$1.11 ▼ $10.54	$46.18M	1.51	257,450 shs	346,257 shs
CORT Corcept Therapeutics	$70.33 -0.9%	$71.18	$33.34 ▼ $117.33	$7.41B	0.2	863,588 shs	866,233 shs
JAZZ Jazz Pharmaceuticals	$123.11 +2.1%	$112.73	$95.49 ▼ $148.06	$7.47B	0.34	842,579 shs	726,062 shs
RPRX Royalty Pharma	$36.32 +0.0%	$36.17	$24.05 ▼ $38.00	$21.18B	0.55	3.04 million shs	2.67 million shs

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ANVS Annovis Bio	0.00%	-12.75%	-16.68%	+19.70%	-75.21%
CORT Corcept Therapeutics	0.00%	-1.98%	+4.05%	-10.62%	+104.27%
JAZZ Jazz Pharmaceuticals	0.00%	+4.53%	+4.32%	+13.92%	+7.65%
RPRX Royalty Pharma	0.00%	-0.08%	-0.74%	+11.93%	+31.59%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ANVS Annovis Bio	2.5217 of 5 stars	3.3	3.0	0.0	0.0	2.2	1.7	0.6
CORT Corcept Therapeutics	4.7716 of 5 stars	3.5	2.0	0.0	4.3	3.0	4.2	1.9
JAZZ Jazz Pharmaceuticals	4.5096 of 5 stars	3.4	2.0	0.0	4.0	3.8	2.5	1.3
RPRX Royalty Pharma	4.9836 of 5 stars	3.7	5.0	3.3	3.7	3.6	1.7	2.5

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ANVS Annovis Bio	2.60	Moderate Buy	$18.00	655.67% Upside
CORT Corcept Therapeutics	3.00	Buy	$134.50	91.24% Upside
JAZZ Jazz Pharmaceuticals	2.87	Moderate Buy	$181.43	47.37% Upside
RPRX Royalty Pharma	3.33	Buy	$48.00	32.16% Upside

Current Analyst Ratings Breakdown

Latest CORT, ANVS, RPRX, and JAZZ Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/20/2025	JAZZ Jazz Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$202.00
8/15/2025	JAZZ Jazz Pharmaceuticals	Zacks Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong Sell ➝ Hold
8/8/2025	ANVS Annovis Bio	Zacks Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold
8/6/2025	JAZZ Jazz Pharmaceuticals	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$165.00 ➝ $162.00
8/1/2025	CORT Corcept Therapeutics	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$142.00 ➝ $137.00
8/1/2025	CORT Corcept Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$131.00 ➝ $121.00
7/22/2025	JAZZ Jazz Pharmaceuticals	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$166.00 ➝ $165.00
7/22/2025	RPRX Royalty Pharma	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$40.00 ➝ $42.00
7/15/2025	JAZZ Jazz Pharmaceuticals	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$152.00
7/10/2025	RPRX Royalty Pharma	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$51.00 ➝ $54.00
6/11/2025	JAZZ Jazz Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$202.00

(Data available from 8/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ANVS Annovis Bio	N/A	N/A	N/A	N/A	$0.67 per share	N/A
CORT Corcept Therapeutics	$675.04M	10.98	$1.24 per share	56.63	$6.49 per share	10.84
JAZZ Jazz Pharmaceuticals	$4.07B	1.84	$30.32 per share	4.06	$67.72 per share	1.82
RPRX Royalty Pharma	$2.26B	9.36	$4.19 per share	8.66	$17.56 per share	2.07

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ANVS Annovis Bio	-$24.59M	-$2.04	0.00	N/A	N/A	N/A	-206.01%	-158.26%	N/A
CORT Corcept Therapeutics	$141.21M	$1.13	62.24	38.02	N/A	18.51%	20.10%	16.20%	10/29/2025 (Estimated)
JAZZ Jazz Pharmaceuticals	$560.12M	-$6.73	N/A	6.58	7.76	-9.91%	5.02%	1.73%	11/5/2025 (Estimated)
RPRX Royalty Pharma	$858.98M	$1.73	8.27	7.47	2.37	44.23%	25.54%	14.11%	11/5/2025 (Estimated)

Latest CORT, ANVS, RPRX, and JAZZ Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2025	Q2 2025	ANVS Annovis Bio	-$0.36	-$0.32	+$0.04	-$0.32	N/A	N/A
8/6/2025	Q2 2025	RPRX Royalty Pharma	$1.10	$1.14	+$0.04	$0.05	$750.06 million	$578.67 million
8/5/2025	Q2 2025	JAZZ Jazz Pharmaceuticals	-$5.61	-$8.25	-$2.64	-$11.74	$1.05 billion	$1.05 billion
7/31/2025	Q2 2025	CORT Corcept Therapeutics	$0.23	$0.29	+$0.06	$0.29	$199.40 million	$194.43 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ANVS Annovis Bio	N/A	N/A	N/A	N/A	N/A
CORT Corcept Therapeutics	N/A	N/A	N/A	N/A	N/A
JAZZ Jazz Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
RPRX Royalty Pharma	$0.88	2.42%	N/A	50.87%	5 Years

Latest CORT, ANVS, RPRX, and JAZZ Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
7/18/2025	RPRX Royalty Pharma	quarterly	$0.22	2.48%	8/15/2025	8/15/2025	9/10/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ANVS Annovis Bio	N/A	7.65	7.65
CORT Corcept Therapeutics	N/A	3.06	2.98
JAZZ Jazz Pharmaceuticals	1.17	1.62	1.37
RPRX Royalty Pharma	0.74	1.26	1.26

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ANVS Annovis Bio	15.83%
CORT Corcept Therapeutics	93.61%
JAZZ Jazz Pharmaceuticals	89.14%
RPRX Royalty Pharma	54.35%

Insider Ownership

Company	Insider Ownership
ANVS Annovis Bio	20.80%
CORT Corcept Therapeutics	20.50%
JAZZ Jazz Pharmaceuticals	4.30%
RPRX Royalty Pharma	18.90%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ANVS Annovis Bio	3	19.49 million	15.43 million	Optionable
CORT Corcept Therapeutics	300	105.37 million	83.77 million	Optionable
JAZZ Jazz Pharmaceuticals	2,800	60.66 million	58.05 million	Optionable
RPRX Royalty Pharma	80	583.17 million	472.95 million	Optionable

CORT, ANVS, RPRX, and JAZZ Headlines

Recent News About These Companies

Royalty Pharma PLC $RPRX Shares Acquired by Korea Investment CORP

August 24 at 5:01 AM | marketbeat.com

Royalty Pharma PLC $RPRX Shares Bought by Aberdeen Group plc

August 23 at 4:34 AM | marketbeat.com

Royalty Pharma PLC $RPRX Shares Sold by State of New Jersey Common Pension Fund D

August 22 at 4:27 AM | marketbeat.com

LPL Financial LLC Raises Position in Royalty Pharma PLC $RPRX

August 21 at 3:08 AM | marketbeat.com

Cetera Investment Advisers Buys New Position in Royalty Pharma PLC $RPRX

August 21 at 3:08 AM | marketbeat.com

119,761 Shares in Royalty Pharma PLC $RPRX Purchased by Kovitz Investment Group Partners LLC

August 20, 2025 | marketbeat.com

Invesco Ltd. Purchases 326,525 Shares of Royalty Pharma PLC $RPRX

August 20, 2025 | marketbeat.com

Fox Run Management L.L.C. Cuts Stock Holdings in Royalty Pharma PLC (NASDAQ:RPRX)

August 19, 2025 | marketbeat.com

Fjarde AP Fonden Fourth Swedish National Pension Fund Has $2.73 Million Stock Position in Royalty Pharma PLC (NASDAQ:RPRX)

August 19, 2025 | marketbeat.com

Nuveen LLC Makes New $27.75 Million Investment in Royalty Pharma PLC $RPRX

August 19, 2025 | marketbeat.com

Gulf International Bank UK Ltd Has $699,000 Stock Holdings in Royalty Pharma PLC (NASDAQ:RPRX)

August 19, 2025 | marketbeat.com

Citigroup Inc. Has $10.39 Million Stake in Royalty Pharma PLC (NASDAQ:RPRX)

August 18, 2025 | marketbeat.com

Wealthedge Investment Advisors LLC Takes Position in Royalty Pharma PLC (NASDAQ:RPRX)

August 17, 2025 | marketbeat.com

Brandywine Global Investment Management LLC Decreases Stock Position in Royalty Pharma PLC (NASDAQ:RPRX)

August 17, 2025 | marketbeat.com

22,092 Shares in Royalty Pharma PLC (NASDAQ:RPRX) Acquired by Cookson Peirce & Co. Inc.

August 17, 2025 | marketbeat.com

OneAscent Investment Solutions LLC Buys New Shares in Royalty Pharma PLC (NASDAQ:RPRX)

August 16, 2025 | marketbeat.com

Russell Investments Group Ltd. Reduces Position in Royalty Pharma PLC (NASDAQ:RPRX)

August 15, 2025 | marketbeat.com

Virtu Financial LLC Increases Stock Position in Royalty Pharma PLC (NASDAQ:RPRX)

August 14, 2025 | marketbeat.com

Deutsche Bank AG Sells 1,775,038 Shares of Royalty Pharma PLC (NASDAQ:RPRX)

August 14, 2025 | marketbeat.com

Charles Schwab Investment Management Inc. Has $97.20 Million Stock Position in Royalty Pharma PLC (NASDAQ:RPRX)

August 14, 2025 | marketbeat.com

Henry Fernandez Steps Down from Royalty Pharma's Board of Directors

August 13, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CORT, ANVS, RPRX, and JAZZ Company Descriptions

Annovis Bio NYSE:ANVS

$2.38 +0.00 (+0.08%)

Closing price 08/22/2025 03:59 PM Eastern

Extended Trading

$2.38 0.00 (-0.08%)

As of 08/22/2025 07:58 PM Eastern

Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead product candidate is Buntanetap, which has completed three Phase 1/2 clinical trials for the treatment of Alzheimer's disease (AD), Parkinson's disease, and other chronic neurodegenerative diseases. It is also developing ANVS405, which is in Phase 2 and Phase 3 efficacy studies, an intravenous drug for protecting the brain after traumatic brain injury and/or stroke; and ANVS301, which is in Phase I clinical trials, an orally administered drug to increase cognitive capability in later stages of AD and dementia. The company was incorporated in 2008 and is based in Malvern, Pennsylvania.

Corcept Therapeutics NASDAQ:CORT

$70.33 -0.65 (-0.92%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$69.65 -0.68 (-0.96%)

As of 08/22/2025 07:40 PM Eastern

Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. The company is also developing relacorilant, which is in phase III clinical trial for the treatment of cushing's syndrome; treatment for adrenal cancer and cortisol excess which is in phase 1b clinical trial; treatment for prostate cancer which is in phase II clinical trial; and nab-paclitaxel in combination with relacorilant, which is in phase III clinical trial to treat platinum-resistant ovarian tumors. In addition, it develops dazucorilant, which is in phase II clinical trial for the treatment of amyotrophic lateral sclerosis; miricorilant, which is in phase IIb trial for the treatment of nonalcoholic steatohepatitis; and treatment for antipsychotic induced weight gain that is in phase I trial. The company was incorporated in 1998 and is headquartered in Menlo Park, California.

Jazz Pharmaceuticals NASDAQ:JAZZ

$123.11 +2.58 (+2.14%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$123.20 +0.09 (+0.08%)

As of 08/22/2025 05:29 PM Eastern

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia. It also develops Zanidatamab to treat HER2-expressing gastroesophageal adenocarcinoma (GEA), and patients with HER2-expressing metastatic GEA; Zepzelca for the treatment of patients with select relapsed/refractory solid tumors based on limited response in three solid tumor cohorts; JZP815, a pan-RAF kinase inhibitor that targets components of the mitogen-activated protein kinase; JZP898, a conditionally-activated interferon alpha molecule; Epidiolex to treat LGS, DS, and TSC; Suvecaltamide to treat parkinson's disease tremor; JZP150, a fatty acid amide hydrolase inhibitor program to treat post-traumatic stress disorder; and JZP441 to treat narcolepsy, IH, and other sleep disorders. The company has licensing and collaboration agreements with XL-protein GmbH to extend the plasma half-life of selected asparaginase product candidates; Redx Pharma plc for preclinical activities Ras/Raf/MAP kinase pathway program; and Autifony Therapeutics Limited on discovering and developing drug candidates targeting two different ion channel targets associated with neurological disorders. The company was incorporated in 2003 and is headquartered in Dublin, Ireland.

Royalty Pharma NASDAQ:RPRX

$36.32 +0.01 (+0.03%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$36.32 0.00 (0.00%)

As of 08/22/2025 07:21 PM Eastern

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies. Its portfolio consists of royalties on approximately 35 commercial products and 14 development-stage product candidates that address various therapeutic areas, such as rare disease, cancer, neuroscience, immunology, respiratory, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time